Aqueous extract of paeonia lactiflora and paeoniflorin as aggregation reducers targeting chaperones in cell models of spinocerebellar ataxia 3

Kuo Hsuan Chang, Wan Ling Chen, Li Ching Lee, Chih Hsin Lin, Pin Jui Kung, Te Hsien Lin, Yi Ci Wu, Yih Ru Wu, Yi Chun Chen, Guey Jen Lee-Chen, Chiung Mei Chen

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Spinocerebellar ataxia (SCA) types 1, 2, 3, 6, 7, and 17 as well as Huntington's disease are a group of neurodegenerative disorders caused by expanded CAG repeats encoding a long polyglutamine (polyQ) tract in the respective proteins. Evidence has shown that the accumulation of intranuclear and cytoplasmic misfolded polyQ proteins leads to apoptosis and cell death. Thus suppression of aggregate formation is expected to inhibit a wide range of downstream pathogenic events in polyQ diseases. In this study, we established a high-throughput aggregation screening system using 293 ATXN3/QGFP cells and applied this system to test the aqueous extract of Paeonia lactiflora (P. lactiflora) and its constituents. We found that the aggregation can be significantly prohibited by P. lactiflora and its active compound paeoniflorin. Meanwhile, P. lactiflora and paeoniflorin upregulated HSF1 and HSP70 chaperones in the same cell models. Both of them further reduced the aggregation in neuronal differentiated SH-SY5Y ATXN3/QGFP cells. Our results demonstrate how P. lactiflora and paeoniflorin are likely to work on polyQ-aggregation reduction and provide insight into the possible working mechanism of P. lactiflora in SCA3. We anticipate our paper to be a starting point for screening more potential herbs for the treatment of SCA3 and other polyQ diseases.

Original languageEnglish
Article number471659
JournalEvidence-based Complementary and Alternative Medicine
Volume2013
DOIs
Publication statusPublished - 2013 Apr 2

Fingerprint

Machado-Joseph Disease
Paeonia
Spinocerebellar Ataxias
Huntington Disease
Neurodegenerative Diseases
peoniflorin
polyglutamine
Proteins
Cell Death
Apoptosis

ASJC Scopus subject areas

  • Complementary and alternative medicine

Cite this

Aqueous extract of paeonia lactiflora and paeoniflorin as aggregation reducers targeting chaperones in cell models of spinocerebellar ataxia 3. / Chang, Kuo Hsuan; Chen, Wan Ling; Lee, Li Ching; Lin, Chih Hsin; Kung, Pin Jui; Lin, Te Hsien; Wu, Yi Ci; Wu, Yih Ru; Chen, Yi Chun; Lee-Chen, Guey Jen; Chen, Chiung Mei.

In: Evidence-based Complementary and Alternative Medicine, Vol. 2013, 471659, 02.04.2013.

Research output: Contribution to journalArticle

Chang, Kuo Hsuan ; Chen, Wan Ling ; Lee, Li Ching ; Lin, Chih Hsin ; Kung, Pin Jui ; Lin, Te Hsien ; Wu, Yi Ci ; Wu, Yih Ru ; Chen, Yi Chun ; Lee-Chen, Guey Jen ; Chen, Chiung Mei. / Aqueous extract of paeonia lactiflora and paeoniflorin as aggregation reducers targeting chaperones in cell models of spinocerebellar ataxia 3. In: Evidence-based Complementary and Alternative Medicine. 2013 ; Vol. 2013.
@article{e96d9ce4774342bfb45f0748ee12b74c,
title = "Aqueous extract of paeonia lactiflora and paeoniflorin as aggregation reducers targeting chaperones in cell models of spinocerebellar ataxia 3",
abstract = "Spinocerebellar ataxia (SCA) types 1, 2, 3, 6, 7, and 17 as well as Huntington's disease are a group of neurodegenerative disorders caused by expanded CAG repeats encoding a long polyglutamine (polyQ) tract in the respective proteins. Evidence has shown that the accumulation of intranuclear and cytoplasmic misfolded polyQ proteins leads to apoptosis and cell death. Thus suppression of aggregate formation is expected to inhibit a wide range of downstream pathogenic events in polyQ diseases. In this study, we established a high-throughput aggregation screening system using 293 ATXN3/QGFP cells and applied this system to test the aqueous extract of Paeonia lactiflora (P. lactiflora) and its constituents. We found that the aggregation can be significantly prohibited by P. lactiflora and its active compound paeoniflorin. Meanwhile, P. lactiflora and paeoniflorin upregulated HSF1 and HSP70 chaperones in the same cell models. Both of them further reduced the aggregation in neuronal differentiated SH-SY5Y ATXN3/QGFP cells. Our results demonstrate how P. lactiflora and paeoniflorin are likely to work on polyQ-aggregation reduction and provide insight into the possible working mechanism of P. lactiflora in SCA3. We anticipate our paper to be a starting point for screening more potential herbs for the treatment of SCA3 and other polyQ diseases.",
author = "Chang, {Kuo Hsuan} and Chen, {Wan Ling} and Lee, {Li Ching} and Lin, {Chih Hsin} and Kung, {Pin Jui} and Lin, {Te Hsien} and Wu, {Yi Ci} and Wu, {Yih Ru} and Chen, {Yi Chun} and Lee-Chen, {Guey Jen} and Chen, {Chiung Mei}",
year = "2013",
month = "4",
day = "2",
doi = "10.1155/2013/471659",
language = "English",
volume = "2013",
journal = "Evidence-based Complementary and Alternative Medicine",
issn = "1741-427X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Aqueous extract of paeonia lactiflora and paeoniflorin as aggregation reducers targeting chaperones in cell models of spinocerebellar ataxia 3

AU - Chang, Kuo Hsuan

AU - Chen, Wan Ling

AU - Lee, Li Ching

AU - Lin, Chih Hsin

AU - Kung, Pin Jui

AU - Lin, Te Hsien

AU - Wu, Yi Ci

AU - Wu, Yih Ru

AU - Chen, Yi Chun

AU - Lee-Chen, Guey Jen

AU - Chen, Chiung Mei

PY - 2013/4/2

Y1 - 2013/4/2

N2 - Spinocerebellar ataxia (SCA) types 1, 2, 3, 6, 7, and 17 as well as Huntington's disease are a group of neurodegenerative disorders caused by expanded CAG repeats encoding a long polyglutamine (polyQ) tract in the respective proteins. Evidence has shown that the accumulation of intranuclear and cytoplasmic misfolded polyQ proteins leads to apoptosis and cell death. Thus suppression of aggregate formation is expected to inhibit a wide range of downstream pathogenic events in polyQ diseases. In this study, we established a high-throughput aggregation screening system using 293 ATXN3/QGFP cells and applied this system to test the aqueous extract of Paeonia lactiflora (P. lactiflora) and its constituents. We found that the aggregation can be significantly prohibited by P. lactiflora and its active compound paeoniflorin. Meanwhile, P. lactiflora and paeoniflorin upregulated HSF1 and HSP70 chaperones in the same cell models. Both of them further reduced the aggregation in neuronal differentiated SH-SY5Y ATXN3/QGFP cells. Our results demonstrate how P. lactiflora and paeoniflorin are likely to work on polyQ-aggregation reduction and provide insight into the possible working mechanism of P. lactiflora in SCA3. We anticipate our paper to be a starting point for screening more potential herbs for the treatment of SCA3 and other polyQ diseases.

AB - Spinocerebellar ataxia (SCA) types 1, 2, 3, 6, 7, and 17 as well as Huntington's disease are a group of neurodegenerative disorders caused by expanded CAG repeats encoding a long polyglutamine (polyQ) tract in the respective proteins. Evidence has shown that the accumulation of intranuclear and cytoplasmic misfolded polyQ proteins leads to apoptosis and cell death. Thus suppression of aggregate formation is expected to inhibit a wide range of downstream pathogenic events in polyQ diseases. In this study, we established a high-throughput aggregation screening system using 293 ATXN3/QGFP cells and applied this system to test the aqueous extract of Paeonia lactiflora (P. lactiflora) and its constituents. We found that the aggregation can be significantly prohibited by P. lactiflora and its active compound paeoniflorin. Meanwhile, P. lactiflora and paeoniflorin upregulated HSF1 and HSP70 chaperones in the same cell models. Both of them further reduced the aggregation in neuronal differentiated SH-SY5Y ATXN3/QGFP cells. Our results demonstrate how P. lactiflora and paeoniflorin are likely to work on polyQ-aggregation reduction and provide insight into the possible working mechanism of P. lactiflora in SCA3. We anticipate our paper to be a starting point for screening more potential herbs for the treatment of SCA3 and other polyQ diseases.

UR - http://www.scopus.com/inward/record.url?scp=84875463971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875463971&partnerID=8YFLogxK

U2 - 10.1155/2013/471659

DO - 10.1155/2013/471659

M3 - Article

C2 - 23533486

AN - SCOPUS:84875463971

VL - 2013

JO - Evidence-based Complementary and Alternative Medicine

JF - Evidence-based Complementary and Alternative Medicine

SN - 1741-427X

M1 - 471659

ER -